

CURRICULM VITAE

Valerie A. Sorkin-Wells, M.D

Precision Trials
3815 East Bell Road, Suite 4500
Phoenix, AZ 85032
602-931-4507

Education:

1976-1979 Bachelor of Science, Microbiology
Ohio State University

1979-1982 University of Toledo Medical School
Toledo, Ohio
M.D.

Postgraduate Training:

1982-1986 Internship & Residency, Sinai Hospital of Baltimore
OB/GYN four year Residency Program
Baltimore, MD

Professional Experience:

2006-present Investigator
Precision Trials (formerly Arizona Wellness Center for Women
Research Department)
Phoenix, AZ

1998-present Obstetrics & Gynecology/Investigator
Arizona Wellness Center for Women
Phoenix, AZ

1986-1998 Obstetrics & Gynecology/ Investigator
Obstetrics & Gynecology Consultants P.C.
Phoenix, AZ

Valerie Sorkin-Wells. M.D.
Curriculum Vitae
Page 2

Professional Memberships:

American Associates of Gynecologic Laparoscopists
Arizona Medical Association
Maricopa County Medical Society

Hospital Appointments:

2008-Present	Chairman, Physicians Leadership Committee Paradise Valley Hospital Phoenix, AZ
2006-Present	Treasurer, Medical Executive Committee Paradise Valley Hospital Phoenix, AZ
2004- 2006	Member at Large, Medical Executive Committee Paradise Valley Hospital Phoenix, AZ
2002-2004	Treasurer, Medical Executive Committee Paradise Valley Hospital Phoenix, AZ
2000-2002	Member at Large, Medical Executive Committee Paradise Valley Hospital Phoenix, AZ
2000-2002	National Representative of Paradise Valley Hospital Physicians Leadership Group.
1998-2000	Member at Large, Medical Executive Committee Paradise Valley Hospital Phoenix, AZ
1998	Board of Directors Lincoln PPG
1997-2000	PacifiCare Regional QA Task Force

Valerie Sorkin-Wells, M.D.
Curriculum Vitae
Page 3

1991-1992	Chairman, OB GYN Committee Phoenix Baptist Hospital Phoenix, AZ
1991-1992	Co-Chairman, Perinatal Committee Phoenix Baptist Hospital
1988-1994	Quality Assurance Committee HSAG

Hospitals:

Paradise Valley Hospital- active
Scottsdale Healthcare Shea – active
Scottsdale Health Thompson Peak

Licenses/Certifications:

Arizona # 15716

Board Certification:

American Board of Obstetrics & Gynecology 1996-2009

Specialty Training:

DaVinci robotic Surgery Training
Intuitive Surgical
Houston, TX
12/2007

Essure Training
Conceptus Inc.
Phoenix, AZ
12/2002

INCON Therapy
Next Era Medical
Columbus, OH
2/1999

Valerie Sorkin Wells, M.D.
Curriculum Vitae
Page 4

Laser Surgery
Lap Burch
Ethicon, Inc
Phoenix, AZ
1996

Jay Cooper, M.D
Phoenix, AZ
1989

Microsurgery
San Francisco, CA
Zolten Zsabo, MD
1986

Publications:

Sorkin-Wells, et al: "External Version for Breech Presentations," Maryland Medical Journal, 36:425-428, 1987

Research Experience:

A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of XXXXX daily and, with XXXXX daily in Premenopausal women with hypoactive sexual desire disorder.

A Randomized, Multi-center, Double-Blind, Placebo-Controlled Trial, to demonstrate the safety and efficacy of Daily XXXXX and XXXXX daily for the treatment of vasomotor symptoms in postmenopausal women.

A Phase II, Multi-centered, Randomized, Placebo-controlled, Double-blind study of the XXXXX in pre-menopausal women with symptomatic leiomyomata

A Phase III Open-Label, Single Arm Study to Assess the Safety of XXXXX Injection for Minimal-to-Moderate Sedation in patients undergoing Minor Surgical Procedures.

A multi-center, randomized, double-blind phase III study of the efficacy and safety of XXXXX compared to XXXXX for women requiring cervical ripening and induction of labor.

Valerie Sorkin Wells, M.D.

Curriculum Vitae

Page 5

A Phase II, multi-center, double-blind, randomized, placebo-controlled study to evaluate induction of Withdrawal bleeding after administration of XXXXX in women with secondary amenorrhea.

A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate two doses of XXXXX for the management of moderate to severe endometriosis related non-menstrual pelvic pain.

A Randomized, multi-center, double-blind, placebo-controlled trial to compare the effects of 12 weeks of treatment with XXXXX vs. XXXXX on vulvovaginal atrophy in healthy post menopausal women.

A multi-center, double-blind, randomized, placebo-controlled study of XXXXX in the treatment of High-Grade cervical intraepithelial lesions of the uterine cervix.

A Pilot clinical study to evaluate the efficacy of XXXXX in the treatment of the signs and symptoms of atrophic Vaginitis.

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Multiple-Dose study of the XXXXX Efficacy and Safety of Intravenous XXXXX versus Placebo over 48 hours for the Treatment of Postoperative Pain After Gynecologic Surgery

Evaluating the Safety and Efficacy of XXXX in the treatment of Vaginal Atrophy in Postmenopausal Women

Evaluating the Safety & Efficacy of XXXX, vaginal cream compared with Metro Gel vaginal cream for the Treatment of Bacterial Vaginosis

Evaluating the Safety & Efficacy of XXX, combination pack in bedtime versus daytime administration

Evaluating the Safety & Efficacy of XXXX, vaginal ointment, plus XXXX external vulvar cream of XXX, vaginal cream in the Treatment of Vulvovaginal Candidiasis.

Evaluate the dosing optimization study of XXXX for Endometriosis

Evaluate the Safety & Efficacy of Triphasic Oral Contraception

Evaluating the Safety & Efficacy in a double-blinded study of XXXX versus Placebo in Subjects with Endometriosis

Valerie Sorkin Wells, M.D.

Curriculum Vitae

Page 6

Evaluating the Safety & Efficacy of XXXX estrogen combination in Postmenopausal Women

Evaluating XXXX for Contraceptive use

Evaluating XXX in Women using XXXX to Depo-Provera for Contraception

Evaluate the Safety & Efficacy of XXXX in the ovulatory, endocrine and metabolic abnormalities of Women with Polycystic Ovary Syndrome

Evaluating the Safety & Efficacy of XXXX administered with estrogen to Postmenopausal Women in a Phase II Trial

Evaluation of XXX, estrogen with placebo on the Uterus in a Healthy Postmenopausal Woman

Evaluating the XXX Female Condom

Evaluation of Two currently marketed medications for Dysmenorrhea

Evaluation of Three currently marketed products for the Treatment of Estrogen Replacement Therapy

Evaluation of Fixed Doses of XXXX & XXXX acetate for Treatment of Estrogen Replacement Therapy

Evaluation of Triphasic Oral Contraceptive pills containing XXXX

Evaluation of XXXX for the Treatment of Gardnerella Vaginitis

Evaluate Dose Response to the endometrial histologic effects of XXXX compared to placebo in estrogen primed Postmenopausal Women

Evaluation of the XXXX as a barrier Contraceptive Method

Comparative Study for Triphasic Combination Oral Contraception

Evaluation of XXXX administered 5 days + 2day placebo cream compared to XXXX for 7 days in patients with candidiasis

Evaluation of XXXX for Treatment of Pelvic Inflammatory Disease

Valerie Sorkin Wells, M.D.

Curriculum Vitae

Page 7

Evaluation of XXXX sustained release management of primary Dysmenorrhea

Evaluation of XXXX sustained release treatment of postoperative Episiotomy

Evaluation of XXXX in the Treatment of Moniliasis

A Multicenter, Randomized, Double-Blind, Study to Evaluate the Safety And Efficacy of XXXX versus XXXX versus Placebo in Women Diagnosed with Overactive Bladder Who Have Symptoms of Predominant or Pure Urge Incontinence

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Demonstrate the Safety and Efficacy of XXXX for the Treatment of Vasomotor Symptoms in Postmenopausal Women

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Compare the Efficacy and Safety of XXXX vs. XXXX Vulvovaginal Atrophy in Healthy Postmenopausal Women

A Randomized, Multicenter, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of XXXX for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women

A Phase II, Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate Induction of Withdrawal Bleeding After Administration of XXXX in Women with Secondary Amenorrhea

A Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy of XXXX Compared to Conventional Oral Contraceptive Therapy for the Treatment of Cyclic Pelvic Pain in Women

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of an XXXX for the Prevention of Pregnancy in Women

A Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of XXXX When Administered with XXXX for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects with Known Risk Factors for PONV Who are Undergoing Surgical Procedures Associated with an Increased Emetogenic Risk

Valerie Sorkin Wells, M.D.

Curriculum Vitae

Page 8

A Randomized, Double Blind, Multicenter, Parallel Group, Balanced, Stratified, Phase 3 Study to Evaluate the Efficacy and the Safety of XXXX Following Elective Abdominal or Gynecological Laparoscopic Surgery

Comparison of the Safety and Efficacy of XXXX in the Treatment of Iron Deficiency Anemia Secondary to Heavy Uterine Bleeding”

Comparison of the Safety and Efficacy of XXXX in Subjects who Display Postpartum Anemia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of XXXXX in Endometriosis

A Phase II, Randomized, Double-Blind, Placebo-Controlled Twice-Daily Dosing Study of XXXX in Endometriosis

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of XXXX Breast Disease in Otherwise Healthy, Premenopausal Women

A 12-Month, Open Label, Multicenter Study to Evaluate the Safety of XXXX During the Menstrual Cycle in Women with Heavy Menstrual Bleeding Associated with Menorrhagia

A phase II, Multicenter, Randomized, Placebo Controlled, Double-Blinded Study of XXXX in Menopausal Women with Symptomatic Leiomyomata

A Double Blind, Randomized, Placebo Controlled, Efficacy and Safety of XXXX for the Treatment of Vasomotor Symptoms Associated with Menopause.

An Open Label Study of the Contraceptive Efficacy of an Extended Regime of XXXXX and XXXXX

Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses of the XXXXX contraceptive for a maximum of 3 years in women ages 18 to 35

A Multi-center, Double blind, Randomized, Placebo controlled study of XXXXX in the treatment of high grade cervical intraepithelial lesions of the uterine cervix.

Whole Blood collection Protocol for XXXXX Assay Clinical Trial in Women with Ovarian Tumors

Valerie Sorkin Wells, M.D.

Curriculum Vitae

Page 9

A Phase III Randomized, Double Blind, Placebo Controlled, Multi-center, Parallel-group, Multiple-Dose study of the XXXXX Efficacy and Safety of IV XXXXX versus Placebo over 48 hours for the treatment of Postoperative Pain after Gynecologic surgery.

A Multi-center, Open-label, Safety and Efficacy, Two Year Extension study of the XXXXX in Premenopausal Women with Symptomatic Leiomyomata who have previously completed study XXXXX.

Open-label study of the safety and efficacy of a new low dose oral contraceptive containing XXXXX and XXXXX

A Phase II, Randomized, Double-blind, Active-controlled Study to Assess the Safety and Efficacy of XXXXX in Subjects with Endometriosis.

A twelve month, open-label, safety trial of XXXXX daily in women with Hypoactive Sexual Desire Disorder.

A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of XXXXX daily and XXXXX daily in Premenopausal women with hypoactive sexual desire disorder.

A randomized, double-blind, placebo-controlled, multi-center, 52 week study to evaluate the endometrial safety of XXXXX in naturally postmenopausal women with hypoactive sexual desire disorder.

A Phase 2, 18 week, double blind, placebo controlled, multi-center study evaluating the safety and efficacy of XXXXX combination cream with XXXXX and Placebo in the treatment of Vulvar Vestibulitis Syndrome.

A 12 month, open label, multi-center study to evaluate the safety of a XXXXX oral dose of a new modified-released XXXXX formulation administered three times daily as needed for up to 5 days during the menstrual cycle in women with heavy menstrual bleeding associated with menorrhagia.

A phase II, multi-center, randomized, placebo controlled, double blind study of the selective XXXXX in pre-menopausal women with symptomatic leiomyomata.

A Phase III Open-Label, Single Arm Study to Assess the Safety of XXXXX Injection for Minimal-to-Moderate Sedation in patients undergoing Minor Surgical Procedures.

Valerie Sorkin Wells, M.D.
Curriculum Vitae
Page 10

A multi-center, randomized, double-blind phase III study of the efficacy and safety of XXXXX compared to XXXXX for women requiring cervical ripening and induction of labor.

A phase III, randomized, double blind, dose-controlled study to assess the efficacy and safety of XXXXX injection for minimal-to-moderate sedation in patients undergoing flexible Bronchoscopy.

A Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of XXXX

When Administered with XXXX for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects with Known Risk Factors for PONV Who are Undergoing Surgical Procedures Associated with an Increased Emetogenic Risk

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Multiple-Dose Study of the Analgesic Efficacy and Safety of Intravenous XXXXX Versus Placebo over 48 hours for the Treatment of Postoperative pain after Gynecologic Surgery

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Repeated-Dose Study of the Analgesic Efficacy and Safety of Intravenous Acetaminophen versus Placebo for the Treatment of Postoperative Pain after Laparoscopic Surgery

A multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses of the ultra low dose XXXXX contraceptive intrauterine system for a maximum of 3 years in women 18 to 35 years of age
An open label study of the contraceptive efficacy of an extended regime of XXXXX.

Open-label study of the efficacy of a new low dose oral contraceptive containing XXXXX and XXXXX

A multi-center, randomized, controlled study to investigate the safety and tolerability of XXXXX vs. standard medical care in treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum patients

Updated: May 2008